Elsevier

Pharmacological Research

Volume 45, Issue 2, February 2002, Pages 73-85
Pharmacological Research

Regular Article
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors

https://doi.org/10.1006/phrs.2001.0935Get rights and content

Abstract

Poly(ADP-ribose) polymerases (PARPs) are defined as cell signaling enzymes that catalyze the transfer of ADP-ribose units from NAD+to a number of acceptor proteins. PARP-1, the best characterized member of the PARP family, that presently includes six members, is an abundant nuclear enzyme implicated in cellular responses to DNA injury provoked by genotoxic stress (oxygen radicals, ionizing radiations and monofunctional alkylating agents). Due to its involvement either in DNA repair or in cell death, PARP-1 is regarded as a double-edged regulator of cellular functions. In fact, when the DNA damage is moderate, PARP-1 participates in the DNA repair process. Conversely, in the case of massive DNA injury, elevated PARP-1 activation leads to rapid NAD+/ATP consumption and cell death by necrosis. Excessive PARP-1 activity has been implicated in the pathogenesis of numerous clinical conditions such as stroke, myocardial infarction, shock, diabetes and neurodegenerative disorders. PARP-1 could therefore be considered as a potential target for the development of pharmacological strategies to enhance the antitumor efficacy of radio- and chemotherapy or to treat a number of clinical conditions characterized by oxidative or NO-induced stress and consequent PARP-1 activation. Moreover, the discovery of novel functions for the multiple members of the PARP family might lead in the future to additional clinical indications for PARP inhibitors.

References (161)

  • FR Sallmann et al.

    Characterization of sPARP-1. An alternative product of PARP-1 gene with poly(ADP-ribose) polymerase activity independent of DNA strand breaks

    J Biol Chem

    (2000)
  • S Smith et al.

    Tankyrase promotes telomere elongation in human cells

    Curr Biol

    (2000)
  • RJ Griffin et al.

    The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy

    Biochimie

    (1995)
  • KM Milam et al.

    Disturbances in DNA precursor metabolism associated with exposure to an inhibitor of poly(ADP-ribose) synthetase

    Exp Cell Res

    (1986)
  • G de Murcia et al.

    Poly(ADP-ribose) polymerase: a molecular nick-sensor

    Trends Biochem Sci

    (1994)
  • M Masutani et al.

    The response of PARP knockout mice against DNA damaging agents

    Mutat Res

    (2000)
  • MS Satoh et al.

    NAD(+)-dependent repair of damaged DNA by human cell extracts

    J Biol Chem

    (1993)
  • F Dantzer et al.

    Involvement of poly(ADP-ribose) polymerase in base excision repair

    Biochimie

    (1999)
  • D Ben-Yehuda

    Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype

    Blood

    (1996)
  • S Indraccolo

    Mutator phenotype in human hematopoietic neoplasms and its association with deletions disabling DNA repair genes and bcl-2 rearrangements

    Blood

    (1999)
  • JD Kelly

    Relationship between DNA methylation and mutational patterns induced by a sequence selective minor groove methylating agent

    J Biol Chem

    (1999)
  • T Ruscetti et al.

    Stimulation of the DNA-dependent protein kinase by poly(ADP-ribose) polymerase

    J Biol Chem

    (1998)
  • MA Izquierdo et al.

    Major vault protein LRP-related multidrug resistance

    Eur J Cancer

    (1996)
  • JW Shay et al.

    A survey of telomerase activity in human cancer

    Eur J Cancer

    (1997)
  • I Faraoni et al.

    Clinical applications of telomerase in cancer treatment

    Drug Resist Update

    (2000)
  • B Meldrum et al.

    Excitatory amino acid neurotoxicity and neurodegenerative disease

    Trends Pharmacol Sci

    (1990)
  • J Radons et al.

    Nitric oxide toxicity in islet cells involves poly(ADP-ribose) polymerase activation and concomitant NAD+depletion

    Biochem Biophys Res Commun

    (1994)
  • K Takahashi et al.

    Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia

    Brain Res

    (1999)
  • Y Ding et al.

    Long-term neuroprotective effect of inhibiting poly(ADP-ribose) polymerase in rats with middle cerebral artery occlusion using a behavioral assessment

    Brain Res

    (2001)
  • M Ziegler et al.

    A cellular survival switch: poly(ADP-ribosyl)ation stimulates DNA repair and silences transcription

    Bioessays

    (2001)
  • D D’Amours et al.

    Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions

    Biochem J

    (1999)
  • S Smith et al.

    Tankyrase, a poly(ADP-ribose) polymerase at human telomeres

    Science

    (1998)
  • VA Kickhoefer et al.

    The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase

    J Cell Biol

    (1999)
  • NA Berger

    Poly(ADP-ribose) in the cellular response to DNA damage

    Radiat Res

    (1985)
  • Z Herceg et al.

    Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis

    Mol Cell Biol

    (1999)
  • AB Schroeijers

    The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines

    Cancer Res

    (2000)
  • DJ Hunting et al.

    Specificity of inhibitors of poly(ADP-ribose) synthesis. Effects on nucleotide metabolism in cultured cells

    Mol Pharmacol

    (1985)
  • RJ Griffin

    Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)

    Anticancer Drug Des

    (1995)
  • RJ Griffin et al.

    Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme poly (ADP-ribose) polymerase

    Pharm Sci

    (1996)
  • AW While et al.

    Resistance-modifying agents 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase

    J Med Chem

    (2000)
  • D Weltin et al.

    Effect of 6(5H)-phenanthridinone, an inhibitor of poly(ADP-ribose) polymerase, on cultured tumor cells

    Oncol Res

    (1994)
  • S Boulton et al.

    Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors

    Br J Cancer

    (1995)
  • ZQ Wang et al.

    Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease

    Genes Dev

    (1995)
  • SR Wedge et al.

    3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity

    Br J Cancer

    (1996)
  • JM de Murcia

    Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells

    Proc Natl Acad Sci USA

    (1997)
  • L Tentori et al.

    Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide

    Mol Pharmacol

    (1997)
  • L Tentori et al.

    Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with an inhibitor of poly(ADP-ribose) polymerase

    J Pharmacol Exp Ther

    (1998)
  • L Tentori et al.

    Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds

    Leukemia

    (1999)
  • S Boulton et al.

    Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage

    Carcinogenesis

    (1999)
  • L Liu et al.

    Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents

    Clin Cancer Res

    (1999)
  • Cited by (144)

    • Promising anti- cervical carcinoma and inflammatory agent, Resveratrol targets poly (ADP-ribose) polymerase 1 (PARP-1) induced premature ovarian failure with a potent enzymatic modulatory activity

      2021, Journal of Reproductive Immunology
      Citation Excerpt :

      On the contrary, treatment of irradiated rats with resveratrol significantly decreased the ovarian mRNA level of visfatin and significantly increased mRNA levels of PPAR-1 (Fig. 6). Resveratrol radioprotective effects were previously demonstrated (Catalgol et al., 2012; Tentori et al., 2002; Rouleau et al., 2010), but its potential radioprotective effect on the female reproductive organs is not explored much. Present study found it’s a target as PARP-1 through which it was able to be modulating the expression of inflammatory cytokines, and transcription factors (Loizzi et al., 2008; Adriaens et al., 2009; Kumar and Gupta, 2016).

    • A rapid fluorescent method for the real-time measurement of poly(ADP-ribose) polymerase 1 activity

      2018, Analytical Biochemistry
      Citation Excerpt :

      PARP1 participates in various DNA repair pathways, such as non-homologous end-joining [5], base excision repair/single-strand break repair [6], nucleotide excision repair [7], and others [8]. The abundance of functions and the key role in the regulation of DNA repair systems make PARP1 a promising target for the inhibitors as potential anti-cancer drugs [9–13]. The anti-cancer effect of inhibitors of DNA repair enzymes is based on preventing the restoration of DNA integrity by effective repair systems after the action of ionizing radiation or chemotherapy [14].

    View all citing articles on Scopus
    1

    Corresponding [email protected]

    View full text